LEUVEN, Belgium, July 30
- Shares Acquired From Biggar Limited
ThromboGenics NV (Euronext Brussels: THR), a biotechnology companyfocused on eye disease, vascular disease and cancer, today announces that agroup of private investors based in Belgium have together acquired an 8%stake in the Company. Their stake was purchased from Biggar Limited, acharitable foundation that is ThromboGenics largest shareholder. Biggar nowholds a 9.8% stake in ThromboGenics following this transaction, and hasinformed the company that it intends to remain an important shareholder inThromboGenics for the long term.
This transaction was managed by Petercam.
Prof. Desire Collen, Chairman and CEO of ThromboGenics, commenting ontoday's announcement, said: "We are very pleased that we have been able toattract such a group of high net worth individuals to become shareholders inThromboGenics, particularly given their long term commitment to the Company.We are confident that we will be able to generate significant value for allour shareholders over the next several years based on the exciting prospectsfor microplasmin in the treatment of back of the eye disease, our otherpipeline products, including TB-402 for deep vein thrombosis, as well as thesignificant potential that we see for TB-403 in the treatment of cancer,which was recently licensed to Roche."
ThromboGenics is a biotechnology company focused on discovery anddevelopment of biopharmaceuticals for the treatment of a range of vasculardiseases. The Company has several programs in Phase II clinical developmentincluding microplasmin, which is being evaluated as a treatment forvitreoretinal disorders and as a thrombolytic agent for vascular occlusivediseases. ThromboGenics is also developing novel antibody therapeutics incollaboration with BioInvent International; these include TB-402 (Anti-FactorVIII), scheduled to enter Phase II clinical development by the end of 2008,and TB-403 (Anti-PlGF). ThromboGenics and its development partner BioInvent,have recently signed a license agreement with Roche for TB-403 worth up toEUR500 million plus royalties. A Phase Ib clinical trial with TB-403 hasrecently begun in patients with late stage cancer.
ThromboGenics has built strong links with the University of Leuven andthe Flanders Institute for Biotechnology (VIB) and has exclusive rights tocertain therapeutics developed at these institutions. ThromboGenics isheadquartered in Leuven, Belgium and has subsidiaries in Dublin, Ireland andNew York, U.S. The Company is listed on Eurolist by Euronext Brussels underthe symbol THR. More information is available at http://www.thrombogenics.com.
Important information about forward-looking statements
Certain statements in this press release may be considered"forward-looking". Such forward-looking statements are based on currentexpectations, and, accordingly, entail and are influenced by various risksand uncertainties. The Company therefore cannot provide any assurance thatsuch forward-looking statements will materialize and does not assume anobligation to update or revise any forward-looking statement, whether as aresult of new information, future events or any other reason. Additionalinformation concerning risks and uncertainties affecting the business andother factors that could cause actual results to differ materially from anyforward-looking statement is contained in the Company's Annual Report.For further information please contact: ThromboGenics Chris Buyse, CFO Tel : +32-16-75-13-10 [email protected]
Citigate Dewe Rogerson Amber Bielecka/Sylvie Berrebi/David Dible Tel.: +44(0)207-638-95-71 [email protected]
SOURCE ThromboGenics NV